Subscribe
istock-477013712
Bogdanhoda / iStockphoto.com
1 August 2017Asia-Pacific

Takeda enters $100m licensing agreement with Tesaro

Takeda has entered into an exclusive licensing agreement with biopharmaceutical company Tesaro to develop a novel cancer therapy in Japan.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Takeda faces ‘pay-for-delay’ class-action suit over anti-constipation drug
5 August 2021   Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.


Editor's picks

Bankruptcy judge approves $305m sale of genetics testing company
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025

Editor's picks

Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025

More on this story

Generics
Takeda faces ‘pay-for-delay’ class-action suit over anti-constipation drug
5 August 2021   Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.

More on this story

Generics
Takeda faces ‘pay-for-delay’ class-action suit over anti-constipation drug
5 August 2021   Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.

More features

Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?
Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations